Ravulizumab (Ultomiris)


 CADTH recommends that Ultomiris be reimbursed by public drug plans for the treatment of adult and pediatric patients at least 1 month age older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA), if certain conditions are met.
 should only covered treat adults children (aged or older) who: have aHUS, evidence ongoing progressing TMA (blood clots forming in small blood vessels), damaged dysfunctional organ. may funded who had a kidney transplant, but not those already tried ravulizumab it did work.
 is prescribed consultation nephrologist hematologist. Its cost more than expensive complement inhibitor aHUS.